共 50 条
- [1] Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Wilky, Breelyn A.Kumthekar, PriyaWesolowski, RobertHwang, Jimmy J.Park, Steven I.Proscurshim, IgorYuan, GuojunDupont, Christopher D.Shebanova, OlgaCuillerot, Jean-MarieDow, EdwardRaizer, Jeffrey J.Gentry, CarleenRoss, AinsleyDrouin, EliseWilson, NicholasGoldberg, John M.Buell, JenniferStein, Robert Benjamin
- [2] Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapyANNALS OF ONCOLOGY, 2018, 29Wilky, B. A.Kumthekar, P.Wesolowski, R.Hwang, J. J.Park, S. I.Yuan, G.Dupont, C. D.Lim, M.Shebanova, O.Cuillerot, J-M.Dow, E.Ortuzar, W.Raizer, J. J.Drouin, E.Wilson, N.Gonzalez, A. M.Goldberg, J. M.Buell, J. S.Stein, R. B.Youssoufian, H.
- [3] Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Moore, Kathleen N.Dresher, CharlesLiu, JoyceO'Malley, David M.Wang, Edward WengeWang, Judy Sing-ZanSubbiah, VivekWilky, Breelyn A.Yuan, GuojunDupont, Christopher D.Gonzalez, Ana M.Savitsky, DavidCoulter, SaraShebanova, OlgaDow, EdProscurshim, IgorBuell, JenniferStein, Robert BenjaminYoussoufian, Hagop
- [4] Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibodyPLOS ONE, 2018, 13 (04):Gombos, Randi B.Gonzalez, AnaManrique, MarianaChand, DhanSavitsky, DavidMorin, BenjaminBreous-Nystrom, EkaterinaDupont, ChristopherWard, Rebecca A.Mande, CorneliaDuckless, BenjaminTango, HaoFindeis, Mark A.Schuster, AndreaWeight, Jeremy D.Underwood, DennisClarke, ChristopherRitter, GerdMerghoub, TahaScheer, DavidWolchok, Jedd D.van Dijk, MarcBuell, Jennifer S.Cuillerot, Jean-MarieStein, RobertDrouin, Elise E.Wilson, Nicholas S.
- [5] An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patientsPLOS ONE, 2018, 13 (06):Colston, ElizabethGrasela, DennisGardiner, DavidBucy, R. PatVakkalagadda, BlisseKorman, Alan J.Lowy, Israel
- [6] Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Heery, Christopher RyanCoyne, Geraldine Helen O'SullivanMadan, Ravi AmritSchlom, Jeffreyvon Heydebreck, AnjaCuillerot, Jean-MarieSabzevari, HelenGulley, James L.
- [7] Characterization of the anti-CTLA-4 antibody AGEN1884, including toxicology and pharmacology assessments in non-human primatesJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5Gombos, RandiGonzalez, AnaManrique, MarianaChand, DhanSavitsky, DavidMorin, BenjaminBreous-Nystrom, EkaterinaDupont, ChristopherWard, RebeccaMundt, CorneliaDuckless, BenjaminTang, HaoFindeis, MarkSchuster, AndreaWaight, JeremyUnderwood, DennisClarke, ChristopherRitter, GerdMerghoub, TahaSchaer, Davidvan Dijk, MarcBuell, JenniferCuillerot, Jean-MarieStein, RobertDrouin, EliseWIlson, Nicholas
- [8] Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancerANNALS OF ONCOLOGY, 2018, 29Drescher, C.Moore, K. N.Liu, J. F.O'Malley, D. M.Wang, E. W.Wang, J. S-Z.Subbiah, V.Wilky, B. A.Yuan, G.Dupont, C. D.Gonzalez, A. M.Savitsky, D.Coulter, S.Shebanova, O.Dow, E.Ortuzar, W.Buell, J. S.Stein, R. B.Youssoufian, H.
- [9] Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trialJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (10)Tang, BixiaChen, YuJiang, YuFang, MeiyuGao, QuanliRen, XiubaoYao, LiHuang, GangChen, JingZhang, XiaoshiLi, RongqingZhao, ShuaiGao, MeijuanLuo, RuixuanQi, MengLi, FengZheng, FeiLee, MichaelTao, XiaoluDuan, RongGuo, JunChi, ZhihongCui, Chuanliang
- [10] Open-label, phase I, dose escalation/expansion trial of the anti-SIRPa monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimabANNALS OF ONCOLOGY, 2023, 34 : S485 - S485Gutierrez, M.Jamal, R.Yamamoto, N.Doi, T.Elgadi, M.Ferrada, J. L.Wojciekowski, S. M.Patel, M. R.